The Life Sciences Subchapter of LES South Africa and Licensing Executives Society International ( LESI) present:

A Life Sciences Afternoon Virtual Mini-Seminar

Cannabis products, IP, marketing, branding, and other legal and regulatory matters – Licensing matters from a European, Canadian, South Africa and USA perspective

Date: Thursday, 2 July 2020

Time: 14:30 to 17:00 (SAST) / 8:30-11:00 (EDT)

Webinar: Register here.
(or go to www.lesi.org and click on “Upcoming Events”)

Cost: LES members: USD $20 per person
Non-members: USD $40 per person
ABOUT THE PROGRAM:

_Seminar Description:_ Cannabis products and their commercialisation considering IP protection and regulation are very hot topics around the world. There are some interesting lessons to be learnt. LES SA brings together experts from South Africa, Canada, Europe, and the USA. Our experts will be discussing recent developments relating to the protection of plant-based IP in Europe, South Africa and its unique challenges and opportunities that will require innovative thinking and explore various aspects relating to commercialisation of cannabis products.

**PROGRAM**

**JOANNE VAN HARMELEN** *(PhD, LLB Patent Attorney, ENSafrica)*
Patentability of cannabis plants, cannabinoids and cannabis plant cells and plant breeders’ rights in South Africa

**JANUSZ F. LUTEREK** *(Hahn & Hahn Inc)*
Regulatory aspects for food ingredient cannabis products, including opportunities and challenges for South Africa

**HENK KREBS** *(CEO, AgribioMed)*
Regulatory aspects relating to medicinal cannabis products (growth, manufacturing, export, import, medical registration etc.), including opportunities and challenges for South Africa

**ROB DOCHERTY** *(PhD MBA European Patent Attorney, Symbiosis IP Limited)*
The impact of the Enlarged Board of Appeal of the European Patent Office opinion G3/19 on Cannabis-related patent applications in Europe - how to avoid patent ineligibility.

**CHRISTOPHER DEJARDIN and DAVID BARRANS** *(Cassan Maclean IP Agency Inc)*
Marketing and branding of cannabis and cannabis products (edibles) through a trademark/branding strategy and general patentability of cannabis plants, cannabinoids and cannabis plant cells and plant breeders’ rights issues from a Canadian perspective

**MARGARET POLSON** *(Polson Intellectual Property Law PC)*
IP relating to cannabis plants, cannabinoids, and cannabis plant cells from a USA perspective
SPEAKER BIOS:

CHRISTOPHER DEJARDIN (Canada)
Chris’ practice includes all aspects of trademark prosecution including searching and clearance, filing, oppositions and cancellation proceedings. He is a recognized leader on Internet and domain name issues including registration and arbitration of domain names. Chris is actively involved with the Intellectual Property Institute of Canada (IPIC), where he formerly served as Chair of the Bulletin Committee and Chair of the Trademark Agent Training Committee (TMATC), responsible for the preparation and performance of online courses directed to the continuing education of the agent profession in Canada and has been a speaker at the IPIC - McGill University Summer Courses in IP. He has also been actively involved with the International Trademark Association (INTA) where he formerly served on the editorial board of The Trademark Reporter and as a member of the Non-Traditional Marks Committee.

DAVID BARRANS (Canada)
David completed his Ph.D. in molecular cardiology/cardiovascular genomics, after earning a Master of Health Science in Clinical Biochemistry, and a B.Sc. in Biochemistry, all from the University of Toronto. David also served as a Research Fellow in Cardiology at Harvard Medical School in Boston.

David has practiced for more than 15 years in intellectual property. He is a registered Canadian patent agent before the Canadian Intellectual Property Office (CIPO) and can represent Canadian patent applicants as a patent agent before the United States Patent and Trademark Office (USPTO). David’s practice is focused on the drafting and prosecution of patent applications in diverse areas of technology, particularly in biotechnology, life sciences and biochemistry. He has experience and expertise in advising and assisting clients with worldwide patent portfolio management and filing strategies and has given numerous presentations on the patenting process to audiences in the legal and academic communities.

ROB DOCHERTY (Europe)
Symbiosis IP is a patent firm specialising in the protection and enforcement of intellectual property in the Life Sciences with a focus on University technology transfer and start-up companies. Rob has more than 20 years’ experience handling patent applications directed to plants, for example Papaver somniferum, Jatropha curcas, Brassica napus, industrial hemp and plant feedstock for application in biofuels. This includes both transgenic applications with forward and reverse genetic approaches.

G3/19 published on 14 May 2020 and will have an impact in relation to any European patent applications filed after 1 July 2017 to the extent that the application discloses plants or animals obtained exclusively by a biological process. Rob will explain how claim drafting for European applications needs to be modified to address future issues to avoid the problems of patent ineligibility considering G3/19.
MARGARET POLSON (USA)
Margaret Polson is founder and principal attorney for Polson Intellectual Property Law. Overseeing the preparation and prosecution of utility and design patent applications, trademarks, and copyrights, she also assists clients with licensing and intellectual property strategy and management, patent portfolio management, and enforcement.

Ms. Polson also specializes in helping start-ups spend their limited intellectual property budget wisely, having counsel hundreds of start-ups and individual inventors during her career. She is a frequent speaker on the intellectual property of cannabis and on design rights and is a past Chair of the Industrial Designs Committee of the American Intellectual Property Law Association (AIPLA) and is chair of the AIPLA Design Boot Camp programming committee.

JOANNE VAN HARMELEN (South Africa)
Dr. Joanne van Harmelen leads the Biotechnology and Life Sciences Cluster in ENSafrica’s Intellectual Property (“IP”) department. She is a qualified patent attorney specialising in patent filing and prosecution in the biotech and pharmaceuticals sectors. Joanne holds a PhD in medical microbiology and vaccine development. She has extensive experience in the field of biotechnology and life sciences, having prepared and filed patent applications locally and in foreign jurisdictions in the fields of microbiology, biochemistry, molecular medicine, agrobiology, bioremediation, bioprocessing, biopharmaceuticals, nutraceuticals, cosmetics, and food sciences. Joanne is also experienced in the preparation and filing of plant breeders’ rights applications.

JANUSZ F. LUTEREK (South Africa)
Janusz holds degrees in both Chemical Engineering from the University of Pretoria and Law from UNISA and is a registered Attorney, Patent Attorney, and a Professional Engineer. In 1997 Janusz became a partner of Hahn & Hahn attorneys, a boutique law firm founded in 1951 and specializing in technology law and intellectual property law. Janusz is a Custodian Member of the South African Association for Food Science and Technology (SAAFoST) and sits on the Council of FSI of the Consumer Goods Council of South Africa as well as sitting on the Food Law Advisory Group of the Department of Health. Janusz has assisted many leading listed companies as well as SAAFoST with their various Foodstuffs, Cosmetics, and Disinfectants Act and Regulations, Medicines and Related Substances Act and Regulations, and Consumer Protection Act submissions to various Government Departments and Parliament as well as implementation in their businesses. In particular, Janusz has been extensively involved in the GMO debate and the issue of advertising to children under R429. This in-depth and on-going involvement in the process has given Janusz special insight into Food Law and the Consumer Protection Act.

HENK KREBS (South Africa)
Henk is the CEO of Agribiomed a registered pharmacist and pharmaceutical chemist, with a master’s degree from North-West University and a Bachelor of Law from the University of South Africa. He has in-depth experience with regulatory and compliance processes, having worked closely with various regulatory bodies and health departments. He has extensive networks and relationships within the industry, having served various Fortune 500 pharmaceutical and medical device companies at board level. He is the founder/owner of a group of healthcare companies.